联合检测HE4、CA125和CYFRA21-1在卵巢癌诊断中的应用  

Clinical application of the HE4,CA125 and CYFRA21-1 combined detection in the diagnosis of malignant ovarian tumor

作　　者：田峰 易梦璐 齐素文[2] 王林纤[3] 

机构地区：[1]广东省深圳市光明新区人民医院检验科,广东深圳518110 [2]深圳大学医学院生物医学工程系,广东深圳518060 [3]湖南省肿瘤医院检验科,湖南长沙410006

出　　处：《检验医学》2014年第7期697-700,共4页Laboratory Medicine

基　　金：广东省自然科学基金资助项目(S2013040014682)

摘　　要：目的探讨血清人附睾蛋白4(HE4)、糖类抗原125(CA125)和细胞角蛋白19片段(CYFRA21-1)联合检测对卵巢癌诊断的临床价值。方法选择卵巢癌患者85例、卵巢良性肿瘤患者85例和健康妇女(正常对照组)85名,采用酶联免疫吸附试验(ELISA)检测血清HE4水平,采用化学发光法检测血清CA125、CYFRA21-l水平,比较各组3项指标的检测结果并计算阳性率及联合检测的阳性率。结果卵巢癌组血清HE4、CA125和CYFRA21-1水平明显高于卵巢良性肿瘤组和正常对照组(P<0.01)。卵巢癌组HE4、CA125和CYFRA21-1的阳性率分别为88.24%、74.12%和77.65%,三者联合检测的阳性率为98.82%。结论 HE4、CA125和CYFRA21-1联合检测对卵巢癌具有良好的辅助诊断价值。Objective To investigate the clinical significance of human epididymis 4（ HE4）,carbohydrate antigen125（ CA125） and cytokeratin-19-fragment（ CYFRA21-1） combined detection in the diagnosis of malignant ovarian tumor. Methods The sera of 85 patients with malignant ovarian tumor,85 patients with benign ovarian tumor and 85 healthy women（ healthy control group） were collected. The serum levels of HE4 were determined by enzyme-linked immunosorbent assay（ ELISA）. The serum levels of CA125 and CYFRA21-1 were determined by chemiluminescence assay. The results of the 3 biomarkers were analyzed comparatively in different groups,and the positive rates of the 3individual detections and the combined detection were analyzed. Results Serum HE4,CA125 and CYFRA21-1 levels in malignant ovarian tumor group were significantly higher than those in benign ovarian tumor group and healthy control group（ P〈0. 01）. The positive rates of HE4,CA125,CYFRA21-1 and the combined detection of the 3 biomarkers were 88. 24%,74. 12%,77. 65% and 98. 82%,respectively. Conclusions The combined detection of HE4,CA125 and CYFRA21-1 shows the good auxiliary diagnosis significance for malignant ovarian tumor.

关 键 词：人附睾蛋白4 糖类抗原125 细胞角蛋白19片段 卵巢癌 

分 类 号：R446.62[医药卫生—诊断学]